Expression of ERO1L in gastric cancer and its association with patient prognosis
Expression of ERO1L in gastric cancer and its association with patient prognosis
复制标题
DOI：
10.3892/etm.2017.4782
复制
发表时间：
2017-09-01
影响因子：
2.7
通讯作者：
Feng, Xiaoshan
中科院分区：
文献类型：
--
作者：
Zhou, Bo;Wang, Gongping;Feng, Xiaoshan
本研究旨在评估胃癌中内质网氧化还原素-L样（ERO1L）的表达并确定其与患者预后的关系。本研究共选取105例接受根治性胃切除术的胃癌患者。切除患者的胃癌组织（观察组）和癌旁正常胃组织（对照组）。采用逆转录定量聚合酶链反应、免疫印迹和免疫组化检测肿瘤组织和癌旁组织中ERO1L mRNA和蛋白水平。根据ERO1的表达情况将患者分为两组：阳性组和阴性组。分析ERO1L在胃癌中的表达及其与患者预后的关系。胃癌组织中ERO1 mRNA和蛋白水平显着高于癌旁组织(P
The present study aimed to assess the expression of endoplasmic reticulum oxidoreductin-l-like (ERO1L) in gastric cancer and determine its association with patient prognosis. A total of 105 patients with gastric cancer undergoing radical gastrectomy were selected for the current study. Gastric cancer tissues (the observation group) and normal gastric tissue adjacent to the carcinoma (the control group) were resected from patients. Levels of ERO1L mRNA and protein in tumor tissues and adjacent tissues were detected using reverse transcription-quantitative polymerase chain reaction, western blotting and immunohistochemistry. Patients were divided into two groups: A positive group and negative group, according to the expression of ERO1. The expression of EROlL in gastric cancer and its association with patient prognosis was analyzed. Levels of ERO1 mRNA and protein in gastric cancer were significantly higher than those of adjacent tissues (P